Holly McPherson, MD
Allergy & Immunology · Winston Salem, NCNPI 1043200207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,340 of the $178,825 with a category attached, or 71.2%. 40 manufacturers reported payments, led by AstraZeneca at 43.6% of the total. Among allergy & immunology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,080 payments — averaging $165.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$78K
- GSK$75K
- Regeneron$10K
- Sanofi$4K
- Regeneron Healthcare Solutions, Inc.$2K
- Optinose US, Inc.$1K
- plus $8K from 34 others
What the payments were for
- Consulting fees$20,22611%
- Speaking & faculty fees$127,34071%
- Travel & lodging$8,3385%
- Food & beverage$22,75513%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 279 | $77,940 |
| GSK | 197 | $75,240 |
| Regeneron | 11 | $10,201 |
| Sanofi | 82 | $4,008 |
| Regeneron Healthcare Solutions, Inc. | 84 | $2,060 |
| Optinose US, Inc. | 33 | $1,371 |
| Novartis | 51 | $1,146 |
| Pfizer | 57 | $854 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $597 |
| AbbVie | 29 | $593 |
| Genentech USA, Inc. | 18 | $557 |
| Amgen | 28 | $538 |
| Kaleo, Inc. | 31 | $485 |
| Incyte Corporation | 17 | $462 |
| CSL Behring | 19 | $459 |
| Biocryst US Sales Co., LLC | 15 | $298 |
| Grifols USA, LLC | 10 | $263 |
| Aimmune Therapeutics, Inc. | 4 | $222 |
| Teva Pharmaceuticals USA, Inc. | 18 | $216 |
| Alk-abello, Inc | 5 | $161 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $158 |
| Shire North American Group Inc | 8 | $146 |
| Covis Pharma GmbH | 8 | $129 |
| Pharming Healthcare, Inc. | 5 | $94 |
| Aytu Biopharma, Inc. | 4 | $84 |
| Hospira, Inc. | 6 | $79 |
| Galderma Laboratories, L.p. | 4 | $68 |
| Mylan Specialty L.p. | 4 | $55 |
| Greer Laboratories, Inc. | 2 | $49 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Ionis Pharmaceuticals, Inc. | 2 | $41 |
| LEO Pharma Inc. | 2 | $39 |
| Merck | 2 | $38 |
| USWM, LLC | 2 | $28 |
| Blueprint Medicines Corporation | 1 | $25 |
| Lilly USA, LLC | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $13 |
| Organon | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$178,825 in reported general payments places this provider in the 90th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 41 | $198,539 |
| XolairOmalizumab | 30 | $86,773 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $82,570 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $30,907 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $27,277 |
| Spiriva RespimatTiotropium Bromide | 28 | $19,187 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $12,631 |
| DuleraMometasone/Formoterol | 22 | $9,248 |
| Arnuity ElliptaFluticasone Furoate | 31 | $8,765 |
| XhanceFluticasone Propionate | 13 | $7,677 |
| Epinephrine | 34 | $5,263 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,119 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $4,566 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,554 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $4,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $75,240 | $122,242181 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $77,940 | $39,90976 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $13 | $24,30539 claims |
| MerckDulera | $38 | $9,24822 claims |
| Optinose US, Inc.Xhance | $1,371 | $7,67713 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $5,26334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Winston Salem
- Joel HartmanWinston Salem$749K
- Kent NastasiWinston Salem$31K
- Elizabeth ScannellWinston Salem$12K
- Ingrid HoffmannWinston Salem$9K
- Jason CaldwellWinston Salem$9K
- Maeve OconnorCharlotte$2.2M
- Cristine RadojicicDurham$558K
- Scott ComminsChapel Hill$555K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.